Brand Engagement Network, Inc. (NASDAQ:BNAI) ("BEN"), a provider of enterprise-grade artificial intelligence solutions for the engagement layer of AI, today announced the advancement of Skye Salud to Phase 2 of its clinical evaluation program in Mexico.

 

Developed through a collaboration among BEN, Grupo Skye, and KNOBLOCH Information Group, Skye Salud is an AI-powered medical evidence platform that leverages trusted medical literature, clinical guidelines, and other authoritative sources to support evidence-based clinical information retrieval.

The initiative combines BEN's enterprise-grade AI capabilities, Grupo Skye's leadership in AI innovation across Latin America, and KNOBLOCH Information Group's longstanding presence and trusted relationships within Mexico's healthcare community. Together, the organizations are evaluating how AI-powered access to trusted medical evidence may help improve access to clinical information across healthcare settings in Mexico and Latin America.

The Phase 2 evaluation follows the successful completion of Phase 1 rheumatology testing conducted in a controlled evaluation environment. The initial evaluation assessed platform performance across specialty-specific clinical scenarios, evidence traceability, response quality and source transparency.

Building on those results, the Phase 2 evaluation will expand testing into primary care use cases, where the platform will be assessed across a broader range of clinical topics and physician information needs. The expanded evaluation includes Spanish-language clinical content optimized for the Mexican healthcare environment.